Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by retiredcopon Dec 14, 2020 5:00pm
89 Views
Post# 32102612

RE:RE:RE:RE:PMN update- 2020 in review

RE:RE:RE:RE:PMN update- 2020 in reviewLike I mentioned before...what does the fda do if the treatment is given the green light in Japan or Europe or both....does the fda wait too see what happens overseas or do they taken the  lead and say no to Biogen right now and deal with the questions later ...or do they approve with conditions and save some headaches later. I can't  seem to find the names of the people on that last review board...it would be interesting to see what each of their connections are in the pharma/ research world. Are there any conflicts where some one on the board has ties to different research direction then Biogen...or maybe considered connected to a competitor's company. Overall we can see that the fda is under the thumb of the USA government...what pressures do politicians have on what the fda decides and if they say they are  not influenced ...can there really be a pure organization from influence including the pressure Biogen may have been placing on them....with the positive glowing remarks the fda was making before the review...you have to wonder
<< Previous
Bullboard Posts
Next >>